Biotek-snakken — Januar 2021
-
-
-
KU-spinout satser stort på malariaprotein i kamp mod kræft
En uventet sidegevinst i jagten på en kur mod graviditetsmalaria har sendt dansk virksomhed i retning af en ny kræftbehandling og -diagnostik. En solid kapitaltilførsel er dog en forudsætning for den videre udvikling.
(medwatch.dk)
-
-
ØU har i weekenden Orphazymes som deres topkandidat for 2021 indenfor LifeSience - Det have de ogsåi 2020... Lundbeck, Bavarian og Zealand er outsidere
-
AMBU og GN skulle være de sidste
-
-
Sanofi er ret aggressive for tiden: https://www.kymab.com/news-and-events/news/2021/jan/11/sanofi-acquire-kymab-adding-ky1005-its-pipeline-hu/
-
velbekomme
-
Sutro/EMD's MUC1/EGFR bispecific ADC i klinikken:
https://clinicaltrials.gov/ct2/show/NCT04695847?term=M1231&draw=2&rank=1 -
HANSA BIOPHARMA: LANSERING AV IDEFIRIX I EU FÖLJER PLAN:https://www.svd.se/bors/news_detail.php?newsid=5e5a97de-a51d-4cbc-80a9-10f218fac77b
-
Underligt den bliver ved med at falde....tingene går jo efter planen for Hansa. Det virker lidt hysterisk.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind